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1. Introduction 
There are two major types of diabetes mellitus. Type 1 diabetes is caused by the loss of 
insulin-secreting  cells of the pancreas, which leads to a deficiency of insulin in the human 
body. Type 2 diabetes, known as non-insulin-dependent diabetes mellitus (NIDDM), is 
characterized by insulin resistance of insulin-responsive tissues, such as the muscle and 
adipose tissues. Inability of glucose disposal in these tissues after a meal leads to the 
elevation of glucose level in the blood circulation of the patients. Subsequently, the long-
term effect of hyperglycemia may induce inflammation and oxidative damage to other 
organs and result in many complications such as cardiovascular disease, blindness, 
amputations and renal failure [1]. Unfortunately, type 2 diabetes has high prevalence 
compared to type 1 diabetes in modern societies because the pathogenesis of this disease is 
quite complicated, multi-factorial, and is strongly associated with lifestyle, dietary habits, 
and environmental toxins. In light of these findings, many biomedical researchers and 
clinicians have made great efforts to better understand the pathophysiology of insulin 
resistance and to explore new avenues for the therapy of type 2 diabetes [2]. 
2. Mitochondrial role in the regulation of cellular metabolism 
2.1. Overview of mitochondria 
Mitochondria play important roles in energy metabolism, apoptosis and biosynthesis of 
heme and pyrimidine nucleotides because many vital biochemical reactions take place in the 
organelles. They are also called the powerhouse of mammalian cells because they generate a 
majority of ATP required by the cells. Mitochondria contain key enzymes involved in the 
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tricarboxylic acid (TCA) cycle,  oxidation of fatty acids and the electron carriers of the 
respiratory chain. Metabolic intermediates generated from catabolism of carbohydrates and 
lipids by TCA cycle and oxidation provide reducing equivalents (NADH and FADH2), 
which are funneled into the electron transport chain that consists of a series of respiratory 
enzyme complexes I, II, III and IV. The proton gradient generated from the electron 
transport chain across the inner membrane is then utilized by Complex V to drive the 
phosphorylation of ADP to produce ATP in mitochondria to meet the energy need of the 
cell [3]. Mitochondrion has its own genome, mtDNA, which is a 16.6 kb circular double-
stranded DNA. Mammalian mtDNA encodes 2 rRNAs, 22 tRNAs and 13 polypeptides 
required for the assembly of respiratory enzymes. Each mammalian cell contains several 
hundreds to more than a thousand of mitochondria, and each mitochondrion contains 2-10 
copies of mtDNA to meet different energy needs of the cells. Most importantly, mtDNA is 
naked, compact, and has no efficient DNA repair systems, which renders it prone to free 
radical attack and oxidative damage, and thereby increases its risk of acquiring DNA 
mutations. More than one hundred mutations in mtDNA have been reported to be 
associated with human diseases [4].  
2.2. Regulation of mitochondrial biogenesis 
The mitochondrial biogenesis of the human cells is controlled by extracellular stimuli such 
as low temperature, thyroid hormone, fasting, and exercise through up-regulation of the 
master control, peroxisome proliferator-activated receptor gamma co-activator 1(PC-
1). PC-1 can promote nuclear respiratory factor 1 (NRF-1) and NRF-2 to transcribe their 
target genes that produce many nuclear DNA-encoded mitochondrial proteins and 
mitochondrial transcription factor A (mtTFA), which is a key transcriptional factor for the 
expression of genes encoded by the mitochondrial genome. A great majority of the nuclear 
DNA-encoded proteins are translocated from the cytosol to mitochondria and are assembled 
with mtDNA-encoded proteins to form functional respiratory enzyme complexes on the 
inner membrane. Because mitochondrial biogenesis is a complicated process involved with 
the expression of genes in the two genomes, the communication between mitochondria and 
the nucleus is essential for the proper functioning of mitochondria under different 
physiological conditions [5, 6]. 
2.3. ROS and antioxidant enzyme system in mitochondria 
Mitochondria are also the major source of intracellular reactive oxygen species (ROS). 
Within mitochondria, the superoxide anions (O2.-) are produced in the reaction between O2 
and the electrons leaked out from Complex I and III of the respiratory chain. Subsequently, 
the O2.- can be converted to lipid-permeable hydrogen peroxide (H2O2) by the Mn-
dependent superoxide dismutase (MnSOD), and further changes to more reactive hydroxyl 
radicals (OH.-) via Fenton reaction. There is a set of enzymatic and non-enzymatic ROS-
scavenging system to protect cells from the assault by ROS. The H2O2 can be reduced to H2O 
by catalase (CAT), glutathione peroxidase (Px) or a group of small cysteine-containing 
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proteins such as thioredoxins (Trx) and peroxiredoxins (Prx) [7-9]. Nevertheless, 
overproduction of ROS by defective mitochondria and inefficient antioxidant enzyme 
system may cause oxidative damage to cellular components such as DNA, especially 
mtDNA, proteins, and lipids of target tissues in aging and age-related diseases [10]. It has 
been reported that mitochondrial defects caused by mtDNA mutation or oxidative stress 
also play a role in insulin resistance or diabetes [11-13]. 
3. Mitochondrial dysfunction contributes to insulin resistance and type 2 
diabetes 
In the early 1990s, diabetes has been discovered to be one of the symptoms associated 
with some of the mitochondrial diseases such as mitochondrial encephalopathy, lactic 
acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes and 
deafness (MIDD) syndrome, and patients with these syndromes frequently harbor an A to 
 transition at nucleotide position 3243 of mtDNA [11]. However, until recent years 
diabetes has been usually thought as a secondary effect of aging or age-related diseases in 
patients with an mtDNA mutation. Several recent studies provided the linkage between 
mitochondrial dysfunction or defects in mitochondrial biogenesis and the pathogenesis of 
insulin resistance or type 2 diabetes [12-22]. These studies showed that the tissues of mice 
and human subjects with insulin insensitivity or type 2 diabetes displayed lower 
expression levels of the genes encoding subunits constituting respiratory enzymes, 
decrease in the activities of respiratory enzyme complexes, decreased expression of genes 
involved in mitochondrial biogenesis, mutation or deletion of mtDNA, decrease in the 
bioenergetic capacity, or defects in oxidation of fatty acids. In summary, impairment in 
the mitochondrial OXPHOS function was a common observation in insulin-responsive 
muscle and adipose tissues of diabetic mice or patients. Most importantly, the amplitude 
of the decline of mitochondrial function was found to be related to the severity of diabetic 
symptoms and insulin resistance. These findings support the notion that mitochondrial 
dysfunction is one of the major etiological factors for insulin resistance and type 2 
diabetes. 
4. Mitochondrial DNA alteration causes insulin resistance and type 2 
diabetes 
In order to prove the concept that mitochondrial dysfunction is involved in the 
development of insulin resistance, chemical treatments and genetic manipulation have 
been used to impair mitochondria by alteration of the quantity or quality of mtDNA. Park 
and Lee [23] observed a decrease of insulin sensitivity and impaired activation of insulin 
signaling in mtDNA-depleted muscle cells after chronic treatment with a low dose of 
ethidium bromide (EtBr). Moreover, repletion of mtDNA by removal of EtBr revealed that 
the defects in insulin response could be recovered [23]. Besides, Pravenec et al. [24] 
demonstrated that sequence variations in mtDNA could directly lead to metabolic 
dysregulation that includes glucose intolerance and insulin insensitivity in the conplastic 
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strains of rats. In addition, defects in oxidative phosphorylation caused by treatment of 
oligomycin A, an inhibitor of Complex V, also resulted in a decline of insulin-stimulated 
glucose uptake and inactivation of Akt and IRS-1 in the insulin signaling pathway in 
murine C2C12 myotube cells [25]. The above two lines of experiments clearly 
demonstrated a relationship between mtDNA alteration-induced mitochondrial 
dysfunction and insulin insensitivity. 
4.1. Overproduction of ROS impairs insulin signaling 
Excess ROS production from defective mitochondria has been considered as one of the 
possible unifying factors leading to insulin resistance. Increased concentration of glucose in 
the culture medium was found to significantly increase the ROS level and led to insulin 
resistance in mouse adipocytes and rat primary adipocytes and this effect could be 
prevented by pre-treatment of the adipocytes with the antioxidant N-acetylcysteine [26, 27]. 
After administration with ROS-scavenging enzymes, the insulin sensitivity of muscle cells 
was found to be improved in diabetic mice [28]. Recent studies also demonstrated that the 
amount of superoxide anions generated by mitochondria was increased in four different 
animal models of insulin resistance. Furthermore, it was reported that by addition of 
mitochondria-targeting superoxide dismutase mimetics to decrease the level of ROS could 
alleviate insulin resistance in the insulin-insensitive animals [29]. The mechanisms 
underlying the disruption of insulin signaling by overproduction of ROS have been 
extensively investigated in the past decade. It was demonstrated that, at a certain 
concentration range, ROS could cause an increase in the activity of multiple stress-sensitive 
serine/threonine kinases such as p38 MAPK, JNK, ERK, and NFB and elicit subsequent 
phosphorylation of IRS1 and downstream signaling proteins, which may culminate in the 
compromise of insulin sensitivity [30]. 
4.2. Accumulation of fatty acids impairs insulin signaling 
It is thought that impaired lipid metabolism resulted from defects in  oxidation of fatty 
acids is involved in the disturbance of insulin signaling. Accumulation of intracellular 
lipids by the decreased activities of carnitine palmitoyl transferase (CPT), which 
transports long-chain fatty acids into mitochondria, and long-chain acyl-CoA 
dehydrogenase (LCAD), an enzyme involved in  oxidation of fatty acids, led to insulin 
resistance in insulin-targeting cells [31]. It has been demonstrated that an accumulation of 
fatty acid metabolites, such as diacylglycerol, fatty acyl-CoA and ceramides, could induce 
activation of serine/threonine protein kinases such as PKC and PKC in human tissues 
[32]. In turn, the activation of PKCs phosphorylates IRS-1 and IRS-2 on serine/threonine 
residues to inhibit their enzymatic function and activate the downstream PI3K/Akt 
signaling pathway. The above-mentioned observations suggest that ROS overproduction 
and lipid accumulation elicited by mitochondrial dysfunction may play a role in the 
dysregulation of insulin signaling pathway, which then leads to an attenuation of insulin 
response in affected tissues. 
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4.3. Loss of mild stress-induced AMPKα activation may lead to insulin 
resistance 
Low concentration of ROS is a normal byproduct of cellular functions and is known as the 
secondary messenger in the regulation of intracellular signaling to adapt to the extracellular 
environment. But prolong exposure to oxidative environment may lead to oxidative damage 
to tissue cells and development of diseases. Recent studies revealed that activation of AMPK 
by low dose of ROS is involved in the activation of antioxidant defense system, the influx of 
glycolysis and lipid metabolism [33, 34]. The activation of the downstream targets of AMPK, 
including LUT4, PFK2, and ACC, enhances the  oxidation of fatty acids and the basal and 
insulin-stimulated glucose uptake. Besides, activated AMPK can directly phosphorylate the 
forkhead transcription factor 3a (FOXO3a) to promote its nuclear translocation and 
formation of a transcription complex, which in turn up-regulates the expression of 
thioredoxin and peroxiredoxin [35]. It has been shown that activation of the AMPK-FOXO3a 
pathway via AICAR or metformin, an antidiabetic drug, can decrease the intracellular ROS 
level to improve insulin sensitivity in epithelial cells [35, 36]. These findings indicate that 
mild oxidative stress-elicited activation of AMPK and FOXO3a may safeguard glucose 
homeostatsis and redox status in healthy subjects. Taken together, the decrease in the 
sensitivity and capacity of the response to low-level oxidative stress may play a role in 
insulin insensitivity and type 2 diabetes. 
5. The roles of sirtuins in the maintenance of glucose homeostasis and 
their defects in insulin resistance and type 2 diabetes 
5.1. Introduction of sirtuins 
Sirtuins are a highly conserved family of proteins that exhibit NAD+-dependent protein 
deacetylase and ADP-ribosyltransferase activities. Mammals contain seven sirtuins that are 
confined in different subcellular compartments and regulate diverse functions, such as 
intermediary metabolism, energy homeostasis, and oxidative stress. SIRT1, SIRT6 and SIRT7 
are primarily localized to the nucleus, SIRT2 is a cytosolic protein, and SIRT3, SIRT4 and 
SIRT5 are all located in mitochondria. Sirtuins can regulate the function of enzymes or 
transcription factors by deacetylation of target proteins to cope with nutrient deprivation or 
metabolic stress. In addition to getting involved in the regulation of aging and longevity, 
some of the sirtuins have emerged as important regulators of glucose homeostasis. Sirtuins 
may regulate the activities of some of the regulatory proteins or enzymes involved in the 
insulin-mediated signaling pathways and regulation of mitochondrial function, which in 
turn determine the sensitivity and acuity of biochemical response to high blood glucose of 
the muscle and other peripheral tissues in the human body. 
5.2. SIRT1 and type 2 diabetes 
Accumulating evidence has established that SIRT1 contributes to the pathogenesis of type 2 
diabetes through its effect on oxidative metabolism of the liver, skeletal muscle, adipose 
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tissue, and pancreatic  cells, which indicate that mammalian sirtuins play an essential role 
in the pathogenesis of diabetes and aging-associated metabolic diseases [37]. Increasing 
evidence has suggested that SIRT1 provides overall protection against type 2 diabetes. 
SIRT1-overexpressing transgenic mice showed significant protection from the adverse 
effects of high-fat diet, including hepatic inflammation and impaired insulin sensitivity [38, 
39]. In addition, administration of resveratrol and SIRT1-activating compounds was found 
to improve glucose homeostasis and insulin sensitivity in diet-induced and genetically-
predisposed type 2 diabetic mice [40, 41]. It has been reported that certain sequence 
variations of the SIRT1 gene is strongly associated with type 2 diabetes and obesity in a 
Dutch population [42]. Taken together, these findings suggest that SIRT1 plays a role in the 
pathogenesis of type 2 diabetes and its manipulation has great potential in the prevention 
and treatment of type 2 diabetes in animals and the human. 
5.3. SIRT3 and type 2 diabetes 
In recent years, it has become increasingly clear that reversible lysine acetylation is an 
important posttranslational modification of mitochondrial proteins for the regulation of 
their proper function [43]. A number of proteomics studies have revealed that many key 
metabolic enzymes are acetylated in mitochondria and that their enzymatic activities are 
regulated by changes in acetylation in response to environmental stimuli [44]. Among seven 
members of the sirtuin family, three sirtuins (SIRT3, SIRT4 and SIRT5) are primarily located 
and exert functions in mitochondria. It is a remarkable fact that SIRT3 is the most important 
one regarding the regulation of mitochondrial function because it is responsible for 
deacetylation of the majority of mitochondrial proteins [45]. SIRT3 has been shown to 
control multiple key metabolic pathways through its deacetylase activity in response to 
nutrient deprivation. For example, SIRT3 can deacetylate and activate the mitochondrial 
enzyme acetyl-CoA synthetase 2 (AceCS2). The oxidation of acetate is required for the 
generation of ATP and heat under low-glucose or ketogenic condition [46, 47]. Besides, 
SIRT3 has been shown to deacetylate long-chain acyl-CoA dehydrogenase (LCAD) during 
fasting and thereby promotes -oxidation of fatty acids in the liver mitochondria [48]. 
Recently, some studies provide critical insights into the connection between SIRT3 and the 
pathogenesis of type 2 diabetes and metabolic syndrome. It has been demonstrated that the 
SIRT3 expression in skeletal muscle is reduced in animal models of type 1 and type 2 
diabetes and that results in the decrease of mitochondrial bioenergetic function and over-
production of ROS, which in turn disturbs insulin signaling pathway leading to insulin 
insensitivity [49]. These findings suggest that decreased SIRT3 expression and activity could 
contribute to the metabolic abnormalities in skeletal muscle and pathogenesis of diabetes 
mellitus. On the other hand, mitochondrial dysfunction induced by SIRT3 deficiency in 
pancreaticcells might contribute to the defects in insulin secretion upon stimulation with 
various insulin secretagogues [50]. In a recent study, Hirschey and coworkers [51] showed 
that loss of SIRT3 and resultant mitochondrial protein hyperacetylation contribute to 
obesity, hyperlipidemia, insulin resistance, and steatohepatitis. In addition, they identified a 
single nucleotide polymorphism in the human SIRT3 gene, which causes a loss of the 
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enzyme activity of SIRT3 and is highly associated with the prevalence of metabolic 
syndrome. Abundant evidence has been accumulated to show the importance of reversible 
acetylation/deacetylation of mitochondrial proteins through the action of SIRT3 and its 
potential role in the development of insulin resistance and metabolic disorders. Thus, site-
specific acetylation of mitochondrial proteins and the development of new SIRT3-targeted 
drugs may serve as therapeutic tools to regain normal cellular redox status and energy 
homeostasis in the patients with diabetes and insulin resistance, as well as some of the 
mitochondrial diseases. 
6. Defects in the secretion or function of adipokines as an important 
contributor to insulin resistance or type 2 diabetes 
6.1. Regulation of glucose homeostasis by adipocyte-derived adipokines 
The adipose tissue has traditionally been considered as the site for lipid storage in the 
human body. In recent years, a growing number of studies have revealed that adipose 
tissues can perform endocrine function in secreting several adipokines, which can modulate 
the intermediary metabolism and glucose homeostasis in the peripheral tissues. Adipocyte-
derived adipokines can be divided into two groups according to their action in the 
regulation of glucose metabolism in the mammals. One group is called as “anti-
hyperglycemic adipokines”, which include leptin, adiponectin, omentin, and visfatin. They 
enhance insulin sensitivity in the peripheral tissues to increase glucose utilization and 
decrease the glucose level in blood circulation. Another group of adipokines is termed “pro-
hyperglycemic adipokines” or “pro-inflammatory adipokines”, which include resistin, TNF-
, and RBP4 since they tend to result in an increase of blood glucose and systemic 
inflammation. The imbalance of these two groups of adipokines in blood has been 
frequently observed in patients with insulin resistance [52, 53]. 
6.2. Adiponectin improves insulin sensitivity 
Adiponectin has been considered the most important adipokine due to its higher 
concentration in blood than the others and a decrease in its level is highly correlated with 
type 2 diabetes [54]. Several clinical studies demonstrated that the plasma level of 
adiponectin in obese subjects or patients with type 2 diabetes was significantly lower 
compared with those of normal subjects, and that blood glucose was higher and insulin 
sensitivity was largely decreased in mice with adiponectin deficiency [55, 56]. Besides, 
administration or overexpression of adiponectin in mice can enhance insulin sensitivity and 
glucose utilization to ameliorate the symptoms of insulin resistance [57-59]. This indicates 
that dysregulation of secretion of adipokines from adipose tissues is an important 
contributor for the pathogenesis of type 2 diabetes. Thus, adiponectin has become the most 
attractive adipokine and its function has been gradually unraveled. The underlying 
mechanism of adiponectin in improvement of insulin sensitivity and fatty acid  oxidation 
in skeletal muscle has been demonstrated by Yamauchi and his colleagues [60]. They 
showed that the phosphorylation and activation of AMPK is stimulated when adiponectin 
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binds to adiponectin receptor 1 (AdipoR1), which is a seven-transmembrane receptor 
specifically expressed in the skeletal muscle. In turn, AMPK can induce LUT4 
translocation to the plasma membrane for the increase of glucose uptake. On the other hand, 
the phosphorylated AMPK also activates acetyl-CoA carboxylase to increase the oxidation 
of fatty acids through independent pathways. 
6.3. Bi-directional regulation of the biogenesis and function of mitochondria by 
adiponectin 
Because the decrease of adiponectin expression and the biogenesis and function of 
mitochondria have been observed concurrently in adipose tissues of diabetic mice and 
human subjects [22], some researchers made an effort to elucidate the connection between 
these two cellular events. Koh and coworkers demonstrated that the biogenesis and function 
of mitochondria are important for the maintenance of the adiponectin level in adipocytes 
[61]. They found that adiponectin expression and the mitochondrial content in adipose 
tissues were both reduced in obese mice, and these changes could be reversed by the 
administration of rosiglitazone, a mainstay drug used for treatment of diabetes. Induction of 
mitochondrial biogenesis via adenoviral overexpression of nuclear respiratory factor-1 
(NRF-1) in cultured adipocytes increased the expression of adiponectin. Besides, they found 
that inhibition of mitochondrial function by a respiratory inhibitor or uncoupler decreased 
the level of adiponectin in plasma through activation of ROS-dependent kinase such as JNK. 
This finding suggests that mitochondrial function is linked to adiponectin synthesis in 
adipocytes, and explain the observation that mitochondrial dysfunction is associated with 
the defects of secretion and function of adiponectin, which may lead to systemic insulin 
resistance in obesity and type 2 diabetes. 
On the other hand, a recent study also showed that adiponectin can increase the activity of 
PC-1α and enhance the biogenesis and respiratory function of mitochondria in muscle 
cells [62]. The study provided evidence that adiponectin induces extracellular Ca2+ influx 
through binding to AdipoR1, which is essential for subsequent activation of 
Ca2+/calmodulin-dependent protein kinase kinase  (CaMKK), AMPK and SIRT1. 
Adiponectin ultimately causes an increase in the expression of PC-1by CaMK, a 
downstream target of CaMKK, and increase in the activity of PC-1 by deacetylation of 
SIRT1. These events may in turn elevate the biogenesis and function of mitochondria in 
muscle cells. This new insight into the up-regulation of mitochondrial function by 
adiponectin signaling accounts for the long-term effect of adiponectin on the gene 
expression and provides a biochemical mechanism by which adiponectin improves insulin 
sensitivity of the muscle. 
7. Environmental toxins in mitochondrial dysfunction and insulin 
insensitivity 
Because of the increasing prevalence of type 2 diabetes and metabolic syndrome in 
westernized and industrialized countries, type 2 diabetes is thought as an “epidemic 
Mitochondrial Dysfunction in Insulin Insensitivity 
and Type 2 Diabetes and New Insights for Their Prevention and Management 35 
disease”. With this consideration in mind, scientists conjectured that one of the causative 
factors for type 2 diabetes is probably related to the environmental impact of 
industrialization. A growing body of evidence has indicated that the cause of type 2 diabetes 
and metabolic syndrome is strongly associated with some environmental pollutants and 
mitochondrial toxins. Persistent organic pollutants (POPs), which are organic compounds 
present in many herbicides, insecticides, rodenticides, industrial products and wastes, are 
resistant to photolytic degradation and other chemical or biological destruction processes. 
Owning to these chemical characteristics, POPs can be present for a long time in our 
environment and are accumulated in the human body. Thus, POPs are potential 
environmental risk factors that may affect the human health [63].  
7.1. POPs cause insulin insensitivity 
By analysis of the results from National Health and Nutrition Examination Survey in 
1999-2000, Lee and colleagues found that the prevalence rate of type 2 diabetes was highly 
correlated with the serum concentration of POPs of the American population [64, 65]. 
Contamination of POPs in the human diets might be a contributor to the pathogenesis of 
metabolic diseases including the diabetes. For example, atrazine (ATZ, 2-chloro-4-
ethylamine-6-isopropylamino-S-triazine), one of the herbicides, has been extensively used 
in the corn fields of the United States since the early 1960s. Interestingly, the time and 
areas of ATZ usage are matched with the timing of increase in the incidence of obesity 
and other metabolic syndromes [66, 67]. In addition, long-term exposure of Australian 
outdoor workers to pesticides was found to associate with the disturbance of glucose 
homeostasis, including higher blood glucose and insulin resistance in these subjects [68]. 
It was demonstrated that mice fed with a high-fat diet with POPs-contaminated farmed 
salmon fillet would exaggerate insulin resistance, visceral obesity, and glucose intolerance 
[69]. However, remission of the above symptoms was observed in the mice fed with 
farmed salmon fillet containing low level of POPs [69]. Furthermore, the mortality rate of 
diabetes was positively correlated with the concentration of exposed pesticides [70]. In or-
der to establish a cause and effect relationship in humans, Lee et al. [71, 72] approached 
the Nested case control study to measure the serum levels of POPs in certain population 
before the development of metabolic disease phenotypes. The results revealed that 
increased serum levels of some POPs were highly associated with the incidence of 
adiposity, dyslipidemia, and insulin resistance in a healthy population. This finding 
indicates that exposure to low dose of POP may contribute to excess adiposity and other 
features of metabolic syndrome. 
7.2. Impairment of mitochondrial dysfunction by POPs 
Several studies have demonstrated that environmental toxins could cause oxidative damage 
to mitochondria, the organelles are most susceptible to extrinsic toxins including POPs. It 
has been shown that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), one of the POPs, caused a 
loss of mitochondrial membrane potential and increase of ROS production in mammalian 
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cells. The oxygen consumption rate was increased, due to the uncoupling of respiration, and 
the intracellular ATP content and ADP/O ratio were decreased due to defects in FoF1-ATPase 
in the affected tissues of TCDD-treated mice [73]. Recently, some animal studies revealed 
that POPs could result in insulin insensitivity by impairment of mitochondrial function. It 
was found that chronic exposure to POPs led to mitochondrial dysfunction, morphological 
disruption of mitochondria, decreased activities of respiratory enzymes and decreased 
oxygen consumption rate in the liver and skeletal muscle of mice [74]. Besides, POPs were 
found to down-regulate the expression of leptin in adipose tissues and inactivated insulin 
signaling pathway in the skeletal muscle [75]. These subsequently resulted in insulin resis-
tance, hyperlipidemia, abdominal obesity, and hepatosteatosis in mice and the severity of 
these symptoms was more pronounced in the mice fed on high-fat diets. Moreover, 
mitochondria could be the primary organelles involved in the initiation of inflammation, 
leading to chronic damage in the affected cells or organs. High level of polychlorinated 
biphenyls (PCBs) could promote accumulation of lipids and expression of pro-inflammatory 
adipokines, which decreased the expression of adiponectin and the insulin-stimulated 
glucose uptake in the adipose tissue, leading to systemic obesity and obesity-associated 
atherosclerosis [76]. Taken the findings from the epidemiological survey and the above 
observations together, we suggest that the mitochondrial dysfunction resulted from 
environmental pollutants or toxins play a role in the pathogenesis and prevalence of type 2 
diabetes and insulin resistance. 
8. Improvement of the biogenesis and function of mitochondria by 
exercise and pharmaceutical agents for treatment of insulin resistance 
and type 2 diabetes 
In light of the observations of mitochondrial impairment and increased oxidative stress in 
the patients with type 2 diabetes, it has been thought that an increase of mitochondrial 
function or scavengers of ROS may be effective therapies for these patients. Biomedical 
researchers and clinicians have made considerable efforts in looking for possible ways to 
improve insulin sensitivity in target tissues through up-regulation of the mitochondrial 
function or antioxidant defense system. In this section, we provide experimental evidence to 
demonstrate increase of mitochondrial function and enhancement of the antioxidant defense 
by exercise, treatment of natural products or pharmaceutical agents that can effectively 
ameliorate the symptoms of insulin resistance and type 2 diabetes. 
8.1. Anti-diabetic drugs 
Clinically, the thiazolidinediones (TZDs) have been commonly used to treat patients with 
type 2 diabetes by increasing insulin sensitivity of the muscle and adipose tissues. These 
drugs include pioglitazone, rosiglitazone, and troglitazone, which belong to the group of 
PPAR agonists and can up-regulate the expression of PC-1, a master control of 
mitochondrial biogenesis, and a set of genes involved in the regulation of oxidative 
metabolism [77]. Recent studies revealed that these drugs not only increase insulin 
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sensitivity of cells, but also significantly improve the mitochondrial biogenesis, function and 
morphology in vitro and in vivo [78, 79]. New insights in improving mitochondrial function 
by these anti-diabetic drugs further substantiate the idea that manipulation of mitochondrial 
gene expression is a feasible therapy for the patients with insulin insensitivity or type 2 
diabetes. 
8.2. Regular exercise 
It is worth mentioning that mitochondrial biogenesis can be up-regulated by regular 
exercise through the activation of PC-1and its downstream targets including mtTFA and 
nuclear respiratory factors NRF1 and NRF2 [80, 81], which regulate the expression of a 
number of polypeptides constituting the respiratory enzyme complexes. These molecular 
events culminate in the increase of the bioenergetic function of mitochondria and thereby 
improve the insulin sensitivity of the animals or human subjects doing regular exercise [82]. 
In light of these laboratory findings and the documentation that exercise can alleviate the 
symptoms of patients with type 2 diabetes [83], we suggest that the increase of the 
biogenesis and function of mitochondria is one of the key underlying mechanisms by which 
exercise improves the insulin sensitivity of patients with type 2 diabetes.  
8.3. Natural products and chemicals 
Resveratrol (3,5,4'-trihydroxystilbene), a polyphenol and a well-known antioxidant, has 
been demonstrated to be able to promote mitochondrial biogenesis and fatty acid  
oxidation as well as insulin sensitivity in a mouse model [84]. Resveratrol treatment was 
found to lead to the decrease of PC-1 acetylation through activation of SIRT1 and thereby 
increased the activity of PC-1. In turn, an array of oxidative metabolism-related genes 
was up-regulated and mitochondrial OXPHOS was also elevated in the muscle tissues of the 
mice that had been treated with resveratrol. Moreover, resveratrol increased insulin 
sensitivity in the muscle and protected mice from obesity or insulin resistance when fed on a 
high-fat diet [40]. Additionally, epigallocatechin-3-gallate (EC), which is the most 
effective and abundant catechin in green tea, has been reported to have the antioxidant, anti-
obesity and anti-cancer activities [85]. Several studies on cultured adipocytes and animal 
models demonstrated that EC decreased intracellular levels of ROS and inhibited 
extracellular signal-related kinases (ERK) activation. Moreover, EC was found to activate 
the AMPK to elevate mitochondrial function and -oxidation of fatty acids to decrease the 
accumulation of lipids [86]. All of these downstream effects of EC would be of great use 
to improve insulin sensitivity of the target tissue cells.  
On the other hand, attention should be paid to the therapeutic potential of pyruvate in the 
treatment of diabetes. Pyruvate, an intermediate located at the key position of glucose 
metabolism, has been involved in anaerobic glycolysis and aerobic respiration. Some 
beneficial effects were reported about the administration of pyruvate to patients harboring 
with A3243 or A8344 mutation of mtDNA [87]. Pyruvate can not only improve the 
intracellular redox status by elimination of hydrogen peroxide via non-enzymatic reaction, 
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but also increases ATP production by oxidation of NADH to NAD+ by lactate 
dehydrogenease (LDH). The high level of NAD+ may also enhance the activity of SIRT3, an 
NAD+-dependent deacetylase. In addition, it was found that through the inhibition of TNF 
production and NFB signaling pathways pyruvate could ameliorate the inflammatory 
symptom of insulin resistance [88]. 
8.4. Increase of antioxidant defense  
Treatment of lipoic acid, an antioxidant, could not only decrease the intracellular ROS but 
also enhance insulin-stimulated glucose utilization in skeletal muscle of diabetic animals 
with insulin resistance. Yaworsky et al. [89] demonstrated that lipoic acid significantly 
increased insulin-stimulated glucose uptake of adipocytes through rapid translocation of 
lut1 and lut4 to the plasma membrane via the activation of insulin signaling pathway, 
which includes an increase in tyrosine phosphorylation of IR and IRS-1 as well as activation 
of PI3K and Akt. In addition to its antioxidant activity, lipoic acid was found to significantly 
increase mitochondrial biogenesis and function, including oxygen consumption rate and -
oxidation of fatty acids in adipocytes [90]. All of these effects of lipoic acid were enhanced 
by co-treatment of cells with acetyl L-carnitine (ALCAR), another mitochondrial nutrient 
[91]. These findings suggest that lipoic acid improves insulin sensitivity of adipocytes 
through its ability to elevate the antioxidant capacity and to enhance mitochondrial 
function. In addition, several studies have demonstrated that increasing antioxidant 
capacities by addition of cell- permeabilized MnSOD [29, 30] or overexpression of catalase 
[92, 93] and Px3 [94] to reduce intracellular ROS could improve insulin sensitivity in 
cultured cells or mice. Taken together, the above-mentioned observations clearly indicate 
that therapeutic agents targeting to mitochondria or antioxidant defense system could 
ameliorate the symptoms or insulin insensitivity in cultured cells and animals, and perhaps 
also in the patients. These findings also support the notion that mitochondrial function is 
essential for the maintenance of insulin sensitivity and glucose homeostasis in the human 
body. 
9. Concluding remarks 
This chapter has provided an overview of recent advances in the understanding of 
mitochondrial role in the insulin insensitivity and type 2 diabetes, including the clinical 
observations and possible mechanisms of the insulin insensitivity induced by mitochondrial 
dysfunction in the insulin-responsive tissues. Mitochondrial defects resulted from 
inheritable A3243 or A8344 mutation of mtDNA or environmental pollutants and toxins 
or dysregulated acetylation status of metabolic enzymes may lead to an overproduction of 
intracellular ROS and lipids. These events culminate in the inactivation of the insulin 
signaling pathway and result in insulin insensitivity in muscle and adipocytes. 
Improvement of insulin sensitivity and glucose homeostasis may be achieved by the 
strategy to up-regulate mitochondrial biogenesis, function and antioxidant defense through 
exercise, therapeutic agents, and dietary supplement of antioxidants or natural products 
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(Figure 1). These recent advances not only provide novel information for us to better 
understand the connection between mitochondrial dysfunction and metabolic diseases but 
also lead us to a new avenue in the prevention and treatment of type 2 diabetes or metabolic 
syndrome by the mitochondria-targeting medicine. 
 
 
 
Figure 1. The scheme illustrating the role of mitochondria in the pathogenesis and therapeutic target of 
insulin resistance 
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